Drug-Induced Noninfectious Myocarditis/Pericarditis: A Real-World Pharmacovigilance Study Using the FAERS Database

In this pharmacovigilance study, we aimed to identify the primary suspected drugs associated with drug-induced noninfectious myocarditis/pericarditis by analyzing adverse event reports in the FDA Adverse Event Reporting System database from 2004 to 2023. This study utilizes "Noninfectious Myocarditis/Pericarditis" as a standardized MedDRA query (SMQ), employing the reporting odds ratio, proportional reporting ratio, and Bayesian Confidence Propagation Neural Network methods at the SMQ and Preferred Term levels to monitor potential drug signals, and provides a comprehensive overview of medications associated with drug-induced noninfectious myocarditis/pericarditis. A total of 21,422 relevant adverse event reports were identified, among which 953 drugs were reported as primary suspects. Disproportionality analysis using the reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network methods revealed 193, 163, and 176 drugs, respectively, with potential signals of drug-induced noninfectious myocarditis/pericarditis. Notably, clozapine emerged as the most frequently reported drug, followed by nivolumab and pembrolizumab. Immune checkpoint inhibitors used in antitumor therapy represented the highest proportion of the drug category among the top 30 drugs implicated in adverse event reports. Our findings contribute to a better understanding and prevention of myocarditis/pericarditis, offering valuable reference information for clinical practice.